In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Bausch & Lomb Inc.

Division of Bausch Health Companies Inc.
www.bausch.com

Latest From Bausch & Lomb Inc.

Bookmark
  • News

Bausch Boosts Consumer Growth Platform With Ocuvite Eye Performance

By Malcolm Spicer

In a market expected to reach $2.85bn in worldwide sales in 2024, Bausch Health's Bausch + Lomb business launches Ocuvite Eye Performance, formulated to help strengthen the macula and protect the eye from stressors such as sun light and blue light emitted from digital devices, in the US while considering expanding distribution to other countries.

Dietary Supplements Commercial
Bookmark
  • News

Lumify Ad Launches As Bausch Spends More Behind OTC Eye Care Brands

By Malcolm Spicer

Following first anniversary of Lumify launch, "we're still in a pretty heavy investment period supporting trial because our data suggest that when people use the product, they persist in using the product. And so for now, we got our foot down on of the promotional side," says CFO Paul Herendeen.

OTC Drugs Commercial
Bookmark
  • Analysis

Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal

By Michael Cipriano and Bridget Silverman
The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation
Bookmark
  • Analysis

Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea

By Joseph Haas and John Davis

Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.

Business Strategies Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By